Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
    2.
    发明授权
    Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor 失效
    使用BMP蛋白受体复合物筛选骨代谢活性物质和与II型BMP受体和I型BMP受体共转染的细胞

    公开(公告)号:US06210899B1

    公开(公告)日:2001-04-03

    申请号:US08462467

    申请日:1995-06-05

    IPC分类号: G01N3353

    摘要: The present invention relates to a method for determining whether a compound is capable of binding to a BMP receptor kinase protein complex. The invention further relates to a method for determining the concentration of a BMP receptor ligand in a clinical sample. The invention also relates to a host cell co-transfected with an expression vector comprising a DNA sequence that codes for the BMP receptor kinase protein BRK-3 and an expression vector comprising a DNA sequence that codes for a BMP type I receptor kinase protein. The invention further relates to a host cell co-transfected with an expression vector comprising a DNA sequence that codes for a soluble or incomplete BMP type I receptor kinase protein and a soluble or incomplete BMP receptor kinase protein BRK-3. The invention further relates to a method for determining whether a test compound produces a signal upon binding to a BMP receptor protein complex.

    摘要翻译: 本发明涉及一种用于确定化合物是否能够结合BMP受体激酶蛋白复合物的方法。 本发明还涉及用于测定临床样品中BMP受体配体浓度的方法。 本发明还涉及用包含编码BMP受体激酶蛋白BRK-3的DNA序列和包含编码BMP I型受体激酶蛋白的DNA序列的表达载体的表达载体共转染的宿主细胞。 本发明还涉及用表达载体共转染的宿主细胞,其包含编码可溶性或不完全的BMP I型受体激酶蛋白的DNA序列和可溶性或不完全的BMP受体激酶蛋白BRK-3。 本发明还涉及一种用于确定测试化合物在结合BMP受体蛋白复合物时是否产生信号的方法。

    cDNA encoding a BMP type II receptor
    3.
    发明授权
    cDNA encoding a BMP type II receptor 失效
    编码BMP II型受体的cDNA

    公开(公告)号:US06306622B1

    公开(公告)日:2001-10-23

    申请号:US08334179

    申请日:1994-11-04

    IPC分类号: C07K1400

    CPC分类号: C07K14/71

    摘要: The present invention relates to an isolated BMP, (bone morphogonic protein) receptor kinase protein or soluble fragment thereof, a DNA sequence coding for the BMP receptor kinase protein or the soluble fragment thereof, a recombinant expression vector comprising the DNA sequence, a host cell comprising the recombinant expression vector, and a method of expressing the BMP receptor kinase protein or soluble fragment thereof.

    摘要翻译: 本发明涉及分离的BMP,(骨形态形态蛋白)受体激酶蛋白或其可溶性片段,编码BMP受体激酶蛋白或其可溶性片段的DNA序列,包含DNA序列的重组表达载体,宿主细胞 其包含重组表达载体,以及表达BMP受体激酶蛋白质或其可溶性片段的方法。

    DNA sequence coding for a BMP receptor
    4.
    发明授权
    DNA sequence coding for a BMP receptor 失效
    编码BMP受体的DNA序列

    公开(公告)号:US06248554B1

    公开(公告)日:2001-06-19

    申请号:US08158735

    申请日:1993-11-24

    IPC分类号: C12P2106

    CPC分类号: C07K14/71 A61K38/00

    摘要: The present invention relates to an isolated BMP receptor kinase protein or soluble fragment thereof, a DNA sequence coding for said BMP receptor kinase protein or said soluble fragment thereof, a recombinant expression vector comprising said DNA sequence, a host cell comprising said recombinant expression vector, a method of expressing said BMP receptor kinase protein or soluble fragment thereof, a method for identifying compounds capable of binding to said BMP receptor kinase protein or soluble fragment thereof, a method for determining the amount of such compounds in a sample, and antibodies to said BMP receptor kinase protein.

    摘要翻译: 本发明涉及分离的BMP受体激酶蛋白或其可溶性片段,编码所述BMP受体激酶蛋白或其可溶性片段的DNA序列,包含所述DNA序列的重组表达载体,包含所述重组表达载体的宿主细胞, 表达所述BMP受体激酶蛋白质或其可溶性片段的方法,用于鉴定能够结合所述BMP受体激酶蛋白质或其可溶性片段的化合物的方法,测定样品中所述化合物的量的方法和所述抗体 BMP受体激酶蛋白。

    Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and a type I BMP receptor

    公开(公告)号:US07105290B2

    公开(公告)日:2006-09-12

    申请号:US09742153

    申请日:2000-12-20

    摘要: The present invention relates to a method for determining whether a compound is capable of binding to a BMP receptor kinase protein complex, the method comprising introducing a sample comprising the compound to the BMP receptor kinase protein complex and allowing the compound to bind to the BMP receptor kinase protein complex, wherein the BMP receptor kinase protein complex is comprised of a BMP type I receptor kinase protein and the BMP receptor kinase protein BRK-3. The invention further relates to a method for determining the concentration of a BMP receptor ligand in a clinical sample, the met-hod comprising introducing the sample comprising the ligand to a BMP receptor kinase protein complex and allowing the ligand to bind to the BMP receptor kinase protein complex, wherein the BMP receptor kinase protein complex is comprised of a BMP type I receptor kinase protein and BMP receptor kinase protein BRK-3. The invention further relates to a host cell co-transfected with an expression vector comprising a DNA sequence that codes for the BMP receptor kinase protein BRK-3 and an expression vector comprising a DNA sequence that codes for a BMP type I receptor kinase protein. The invention further relates to a host cell co-transfected with an expression vector comprising a DNA sequence that codes for a soluble or incomplete BMP type I receptor kinase protein and a soluble or incomplete BMP receptor kinsase protein BRK-3. The invention further relates to a method for determining whether a test compound produces a signal upon binding to a BMP receptor protein complex.

    Anti-angiogenic peptides
    6.
    发明授权
    Anti-angiogenic peptides 有权
    抗血管生成肽

    公开(公告)号:US07052705B2

    公开(公告)日:2006-05-30

    申请号:US10263162

    申请日:2002-10-02

    IPC分类号: A61K38/12 A61K38/16 A61K39/00

    摘要: Peptides that specifically interfere with the ability of VEGF165 to interact with the NP-1 receptor or with a VEGFR-2/NP-1 co-receptor complex are disclosed. The inventive peptides are useful to control pathological angiogenesis, such as occurs in cancer and other diseases. The peptides are based on a combination of basic residues contained within Exon 6 of human placental growth factor (PIGF), coupled at the carboxyl terminus to either Exon 8 of VEGF165 or Exon 7 of PIGF. The peptides behave as antagonists of VEGF165 signaling through a mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways. This binding is sufficient to attenuate pathological angiogenesis such as occurs in tumor growth.

    摘要翻译: 公开了特异性干扰VEGF 165与NP-1受体或VEGFR-2 / NP-1共 - 受体复合物相互作用的能力的肽。 本发明的肽可用于控制病理性血管发生,例如发生在癌症和其它疾病中。 所述肽基于包含在人胎盘生长因子(PIGF)的外显子6内的碱性残基的组合,其在羧基末端与PIGF的VEGF 165外显子8或外显子7偶联。 肽通过涉及在VEGFR-2 / NP-1复合物或NP-1上竞争VEGF 165结合的机制而表现为VEGF 165信号传导的拮抗剂,没有 通过其他途径影响VEGF信号传导。 这种结合足以减轻病理性血管发生,例如在肿瘤生长中发生。